Illumina to Apply Rare-Cell Capture to Ovarian Cancer Program; Expects Clinical Apps for MiSeq

Sequencing-based diagnostic panels comprising "between 40 and a few hundred" genes would be a "perfect application for the MiSeq platform," according to Illumina CEO Jay Flatley.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.